Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of August 2023, with a specific transaction date of August 17, 2023. The report serves as a transaction notification regarding a Person Discharging Managerial Responsibilities (PDMR) rather than a periodic financial performance report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to a specific securities transaction:
- Instrument: American Depositary Shares (ADSs), ISIN: US37733W2044
- Transaction Price: $34.8600 per share
- Transaction Volume: 74 shares
- Transaction Type: Acquisition via dividend reinvestment in a 401(k) plan
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely discloses an increase in shareholding for Dr. Hal Barron, a Non-Executive Director, resulting from an automatic dividend reinvestment mechanism.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory compliance notification regarding insider trading rules.
Key Facts for Investor Verification
- Dr. Hal Barron (Non-Executive Director) acquired 74 ADSs on August 17, 2023.
- The acquisition was executed on the New York Stock Exchange (XNYS) at $34.86 per share.
- The transaction was not a discretionary purchase but an automatic reinvestment of dividends within a 401(k) plan.
- This filing contains no operational or financial performance data for GSK plc.